Robert M. Townsend
Bristol-Myers Squibb
49 Papers
330 Citations
Robert M. Townsend is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Belatacept & Abatacept. The author has an hindex of 25, co-authored 49 publications.
Chat about Author
Papers
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Andrew E. Schade,Gary L. Schieven,Robert M. Townsend,Anna M. Jankowska,Vojkan Susulic,Rosemary Zhang,Hadrian Szpurka,Jaroslaw P. Maciejewski +7 more
TL;DR: It is shown that dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses, and the effect is reversible or may be overcome by signals bypassing the TCR, such as phorbol ester.
305
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation.
Jeffrey A. Bluestone,Weihong Liu,Julie M. Yabu,Zoltan Laszik,Amy L. Putnam,M. Belingheri,D. M. Gross,Robert M. Townsend,Flavio Vincenti +8 more
TL;DR: It is reported that the combined belatacept/basiliximab therapy has no long‐term effect on circulating Tregs when compared to a calcineurin inhibitor (CNI)‐treated group and it appears that the basilximab caused a transient loss of both FOXP3+ andFOXP3− CD25+ T cells in the circulation in both treatment groups raising important questions about the use of this therapy in tolerance promoting therapeutic protocols.
233
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
Andrew B. Adams,Nozomu Shirasugi,Thomas R. Jones,Megan M. Durham,Elizabeth Strobert,Shannon R. Cowan,Phyllis Rees,Rose Hendrix,Karen Price,Norma S. Kenyon,David Hagerty,Robert M. Townsend,Dianne Hollenbaugh,Dianne Hollenbaugh,Thomas C. Pearson,Christian P. Larsen +15 more
TL;DR: It is found that the effects of Chi220 treatment were not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity.
207
De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Robert A. Bray,Howard Gebel,Robert M. Townsend,Mustimbo Roberts,Martin Polinsky,L. Yang,H. U. Meier-Kriesche,Christian P. Larsen +7 more
TL;DR: Data suggest that belatacept‐based immunosuppression suppresses de novo DSA development more effectively than cyclosporine‐based Immunosuppressive.
121
CD57+ CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection
Jaclyn R. Espinosa,Jaclyn R. Espinosa,Florence Herr,Gregory K. Tharp,Steven E. Bosinger,M. Song,Alton B. Farris,Roshan P. George,Jennifer Cheeseman,Jennifer Cheeseman,Linda Stempora,Linda Stempora,Robert M. Townsend,Antoine Durrbach,Allan D. Kirk,Allan D. Kirk +15 more
TL;DR: Patients receiving belatacept or conventional calcineurin inhibitor–based immunosuppression were studied and a nonsenescent, cytolytic phenotype associated with CD57 on CD4 T cells was discovered that could identify patients at higher risk for acute rejection on belatACEpt‐based therapy.
112